RU2015143859A - Замедленное высвобождение биматопроста, аналогов биматопроста, простамидов и простагландинов для уменьшения отложений жира - Google Patents

Замедленное высвобождение биматопроста, аналогов биматопроста, простамидов и простагландинов для уменьшения отложений жира Download PDF

Info

Publication number
RU2015143859A
RU2015143859A RU2015143859A RU2015143859A RU2015143859A RU 2015143859 A RU2015143859 A RU 2015143859A RU 2015143859 A RU2015143859 A RU 2015143859A RU 2015143859 A RU2015143859 A RU 2015143859A RU 2015143859 A RU2015143859 A RU 2015143859A
Authority
RU
Russia
Prior art keywords
composition
fat
bimatoprost
deposits
release
Prior art date
Application number
RU2015143859A
Other languages
English (en)
Russian (ru)
Other versions
RU2015143859A3 (https=
Inventor
Скотт М. Виткап
Дэвид Ф. ВУДВАРД
Патрик М. ХЬЮЗ
Original Assignee
Аллерган, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Аллерган, Инк. filed Critical Аллерган, Инк.
Publication of RU2015143859A publication Critical patent/RU2015143859A/ru
Publication of RU2015143859A3 publication Critical patent/RU2015143859A3/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/559Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • A61K9/0051Ocular inserts or implants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Materials For Medical Uses (AREA)
RU2015143859A 2013-04-12 2014-04-09 Замедленное высвобождение биматопроста, аналогов биматопроста, простамидов и простагландинов для уменьшения отложений жира RU2015143859A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361811682P 2013-04-12 2013-04-12
US61/811,682 2013-04-12
PCT/US2014/033558 WO2014169075A1 (en) 2013-04-12 2014-04-09 Sustained release of bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction

Publications (2)

Publication Number Publication Date
RU2015143859A true RU2015143859A (ru) 2017-05-16
RU2015143859A3 RU2015143859A3 (https=) 2018-03-05

Family

ID=51686960

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015143859A RU2015143859A (ru) 2013-04-12 2014-04-09 Замедленное высвобождение биматопроста, аналогов биматопроста, простамидов и простагландинов для уменьшения отложений жира

Country Status (18)

Country Link
US (2) US20140308354A1 (https=)
EP (2) EP3656375A1 (https=)
JP (1) JP2016520561A (https=)
KR (1) KR20150141972A (https=)
CN (2) CN110840899A (https=)
AU (2) AU2014250937A1 (https=)
BR (1) BR112015025915A8 (https=)
CA (1) CA2908731A1 (https=)
CL (1) CL2015003023A1 (https=)
DK (1) DK2983663T3 (https=)
ES (1) ES2785382T3 (https=)
IL (1) IL242006B (https=)
MX (1) MX381097B (https=)
MY (1) MY187802A (https=)
RU (1) RU2015143859A (https=)
SG (2) SG10201701938PA (https=)
WO (1) WO2014169075A1 (https=)
ZA (1) ZA201507217B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX385254B (es) * 2015-04-30 2025-03-14 Allergan Inc Uso de analogos de bimatoprost para el tratamiento de la reduccion de grasa corporal en un sujeto.
US11452703B2 (en) * 2020-05-21 2022-09-27 Peregrine Ophthalmic PTE LTD. Methods and compositions for reducing adipocyte numbers
TW202216159A (zh) * 2020-07-21 2022-05-01 美商歐樂根公司 具高負載前列腺素醯胺之眼內植入物
WO2024218609A1 (en) * 2023-04-18 2024-10-24 Welfare Concepts Limited Composition and method for inducing luteolysis

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2218424A (en) * 1931-05-07 1940-10-15 Teleregister Corp Transmitter and code translator
US4525359A (en) * 1982-12-10 1985-06-25 Greenway Frank L Iii Treatment for selective weight control
US6124344A (en) 1993-12-28 2000-09-26 Allergan Sales, Inc. Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
CA2221110C (en) * 1995-05-18 2009-08-04 Allergan Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents for the treatment of ocular hypertension
DK1562604T3 (da) 2002-10-23 2012-04-02 Sucampo Ag Prostaglandinforbindelser til behandling af fedme
CN100453066C (zh) * 2002-12-04 2009-01-21 参天制药株式会社 利用结膜下储存库的药物释放系统
EP1699432A2 (en) * 2003-12-22 2006-09-13 Aventis Pharmaceuticals, Inc. Injectable phosphatidylcholine preparations
US20080038316A1 (en) 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
WO2007111806A2 (en) * 2006-03-23 2007-10-04 Massachusetts Eye And Ear Infirmary Cyclopentane heptanoic acid compounds for reducing body fat
JP2010506941A (ja) * 2006-10-17 2010-03-04 リセラ,インク. 甲状腺眼症の治療のための方法、組成物及び製剤
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US9095506B2 (en) * 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
US20100247606A1 (en) * 2009-03-25 2010-09-30 Allergan, Inc. Intraocular sustained release drug delivery systems and methods for treating ocular conditions
WO2011109384A2 (en) * 2010-03-02 2011-09-09 Allergan, Inc. Biodegradable polymers for lowering intraocular pressure
WO2012012546A2 (en) 2010-07-21 2012-01-26 Allergan, Inc. METHOD OF CONTROLLING INITIAL DRUG RELEASE OF siRNA FROM SUSTAINED-RELEASE IMPLANTS
WO2014143754A2 (en) * 2013-03-15 2014-09-18 Allergan, Inc. Prostamide-containing intraocular implant
MX385254B (es) 2015-04-30 2025-03-14 Allergan Inc Uso de analogos de bimatoprost para el tratamiento de la reduccion de grasa corporal en un sujeto.

Also Published As

Publication number Publication date
US20140308354A1 (en) 2014-10-16
BR112015025915A8 (pt) 2020-01-14
SG10201701938PA (en) 2017-04-27
CN110840899A (zh) 2020-02-28
NZ712804A (en) 2021-02-26
IL242006B (en) 2020-04-30
CA2908731A1 (en) 2014-10-16
DK2983663T3 (da) 2020-04-20
JP2016520561A (ja) 2016-07-14
MX2015014320A (es) 2015-12-08
AU2014250937A1 (en) 2015-10-22
AU2019203214A1 (en) 2019-05-30
MX381097B (es) 2025-03-12
RU2015143859A3 (https=) 2018-03-05
EP3656375A1 (en) 2020-05-27
KR20150141972A (ko) 2015-12-21
WO2014169075A1 (en) 2014-10-16
CN105101962A (zh) 2015-11-25
EP2983663B1 (en) 2020-01-22
US20160339039A1 (en) 2016-11-24
SG10202109919PA (en) 2021-10-28
HK1221406A1 (en) 2017-06-02
BR112015025915A2 (pt) 2017-07-25
EP2983663A1 (en) 2016-02-17
US10682361B2 (en) 2020-06-16
CL2015003023A1 (es) 2016-06-10
ZA201507217B (en) 2017-09-27
MY187802A (en) 2021-10-26
AU2019203214B2 (en) 2020-10-29
ES2785382T3 (es) 2020-10-06

Similar Documents

Publication Publication Date Title
IL294463A (en) Methods for treating or preventing eye conditions
RU2015143859A (ru) Замедленное высвобождение биматопроста, аналогов биматопроста, простамидов и простагландинов для уменьшения отложений жира
EA200970348A1 (ru) Новые инъецируемые депо-композиции и способ получения таких композиций
RU2011143860A (ru) Безфосфатный лекарственный препарат для лечения глаукомы
RU2014133501A (ru) Способ лечения повышенного внутриглазного давления с помощью внутриглазной системы доставки лекарственного средства с замедленным высвобождением
RU2017115563A (ru) Композиции и способы лечения дисфункции мейбомиевых желез
CA2907721A1 (en) Compositions and methods for topical delivery of prostaglandins to subcutaneous fat
AU2003222049A1 (en) Prostaglandin F2 alpha analogs in combination with antimicrobials for treating glaucoma
UA104945C2 (uk) Фармацевтична композиція лігандів рецепторів секретагогів гормону росту
AR120290A1 (es) Una forma de dosificación parenteral estable de acetato de cetrorelix
SI3085381T1 (en) Orodispersible desmopressin to increase the initial sleep period without disturbing the nostrils
EP3851130A4 (en) INJECTION FORMULATION WITH POLY-L-LACTIC ACID FILLER AND HYALURONIC ACID FILLER CONJUGATE AND METHOD OF MANUFACTURE THEREOF
HRP20140676T1 (hr) Formulacije deoksikolne kiseline i njezinih soli
KR20030016418A (ko) 고안압증 및 녹내장의 치료를 위한 조성물
RU2014149700A (ru) Композиции для доставки активных ингредиентов
ES2764654T3 (es) Combinaciones de prostaglandinas y donantes de óxido nítrico
JP2016520561A5 (https=)
US20120263803A1 (en) Aqueous ophthalmic composition
MX2021011727A (es) Composiciones y metodos para tratar enfermedades oculares.
TW201347774A (zh) 脂肪酸衍生物-聚合物共軛物
WO2014183018A3 (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES THROUGH INHIBITING TGF-β ACTIVITY
JP2013515049A5 (https=)
CN117015391A (zh) 用于由于衰老引起的骨骼肌功能衰退的肌肉功能改善剂
JP2019137698A (ja) Lhrhアナログの水性持続放出組成物
US20160074320A1 (en) Pharmaceutical compostions comprising kisspeptin or derivatives thereof

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20210301